Torrent Pharmaceuticals
Last updated Jul 5, 2026
Evidence Sources
5
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
1
Confidence Coverage
69%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Infectious Disease
- Antibiotic
- Diabetes
- Oral Hypoglycemic
- Cardiology
Highest priority development: Lurasidone Hydrochloride
Portfolio development
Lurasidone Hydrochloride is an owned Torrent Pharmaceuticals portfolio development in Psychiatry · Antipsychotic.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 69%
Active Signals
6
Investigate Priority
0
Opportunity Score
223
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 5, 2026Score 39Torrent Pharmaceuticals submits ANDA for Vericiguat
Cardiology · Heart Failure
- MonitorJul 24, 2026Score 38Torrent's Moxifloxacin Hydrochloride ANDA Receives Approval Status
Infectious Disease · Antibiotic
- MonitorJul 24, 2026Score 38Torrent's Metformin Hydrochloride ANDA090014 Receives AP Status
Diabetes · Oral Hypoglycemic
Related Assets
Portfolio asset pages with evidence-based assessments.
- Lurasidone HydrochlorideModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — PITOLISANT HYDROCHLORIDE (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Lurasidone HydrochlorideModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Torrent Pharmaceuticals right now?
- Which regulatory precedents should Torrent Pharmaceuticals monitor in Infectious Disease and Antibiotic?
- How does Torrent Pharmaceuticals Gains Competitive Edge with Lurasidone Hydrochloride Approval compare to the nearest competitive programs?
- What signals require immediate investigation for Torrent Pharmaceuticals?
- Summarize the strategic implications of recent developments for Torrent Pharmaceuticals.
- Where is the greatest uncertainty in Torrent Pharmaceuticals's competitive positioning?